Five Peptides, One Shared Adversary

Abstract, in plain English

A peptide is a short chain of amino acids — the same building blocks as any protein, only fewer of them. That is the whole difficulty. The body is extremely good at taking apart anything made of amino acids, and it works fast: native GLP-1, one of the hormones copied on this site, survives roughly two minutes in the bloodstream.

So before a peptide can be studied seriously, somebody has to make it last. This desk reads five well-known peptides side by side and asks what each of them did about that single problem. Two were chemically rewritten so the body's cutting enzymes no longer recognise them. Both of those were also tied to a large blood protein so they could ride along at its pace. One was looped into a ring. Two were left almost exactly as nature made them.

That one choice explains a surprising amount: how often each compound is given, what kind of study could ever be run on it, when its side effects arrive and how long they last, and whether it became a medicine at all.

The coalition thesis: durability decides what can be known

The five compounds gathered here belong to five different pharmacological classes. BPC-157 is a cytoprotective fragment of a gastric protein. CJC-1295 is a growth-hormone-releasing hormone analogue. Semaglutide (Ozempic, Wegovy, Rybelsus) is an incretin mimetic. Thymosin alpha-1 (thymalfasin) is a thymic immunomodulator. PT-141 (bremelanotide) is a melanocortin receptor agonist. No two act on the same receptor, and no two are studied for the same outcome.

The organising claim of this desk is that the most portable thing they share is not biology at all. It is a constraint: a peptide is made of the one material the body is most practised at destroying. Proteases in plasma and tissue, dipeptidyl peptidase-IV working at the N-terminus, and filtration at the kidney together give an unmodified peptide a working life measured in minutes. Every peptide that became usable — as a laboratory tool, as an investigational agent, or as an approved medicine — had to answer that constraint before it could be anything else, and the answer it gave sits upstream of nearly everything that follows.

Four answers appear across these five molecules. A peptide can be re-spelled, swapping the residues a protease reads for residues it does not recognise. It can be tethered to serum albumin, the largest and most persistent protein in plasma, and carried at albumin's pace instead of its own. It can be cyclised, closed into a ring that resists unravelling. Or it can be left alone, accepting a short life and being dosed around it.

CJC-1295 and semaglutide use the first two answers in combination, and are the two most durable compounds in the set. PT-141 uses the third. BPC-157 and thymosin alpha-1 use the fourth — one because no sponsor ever redesigned it, one because the molecule is a deliberate copy of something the body already makes. This is not a pharmacokinetics page and duration is not the subject here; it is the predictor. The rest of this review follows that single choice forward into what could ever be studied about each compound, and what was.

Terminology: what 'research peptide' does and does not denote

The phrase research peptide is a supply-chain description, not a pharmacological one, and reading it as a category is the most common error a newcomer makes. It denotes a peptide sold for laboratory use, labelled not for human consumption, and distributed outside the pharmaceutical approval system. It says nothing whatever about the molecule's mechanism, its evidence base, or its risk.

The five compounds reviewed here make the point plainly. Semaglutide is an approved prescription medicine with several indications and outcome trials enrolling thousands of participants ^[15][16]. Bremelanotide has been approved in the United States since June 2019 for one narrow indication — acquired, generalised hypoactive sexual desire disorder in premenopausal women — and is given as a 1.75 mg subcutaneous dose only when needed ^[25][27]. Thymalfasin is approved as a drug in more than thirty-five countries, though not in the United States ^[19]. CJC-1295 and BPC-157 are approved nowhere and are handled strictly as research chemicals. All five nonetheless move through research-supply channels, where the labelling is identical for every one of them.

Two consequences follow, and this desk states both at the outset. First, regulatory status is a fact about jurisdictions, sponsors and completed trials, not a verdict on how interesting a molecule's biology is. Second, material sold as a research chemical carries no verification of identity, purity or concentration, which is a problem entirely separate from whether the compound does anything at all.

What generalises across classes, and what does not

A cross-class reading earns its place only if it is honest about its own boundary. Three things in this literature genuinely travel between compounds.

Duration travels. How long a peptide persists sets how often it must be given; the dosing interval sets what kind of study is operationally possible; the study design sets which endpoints are reachable at all. That chain holds for all five compounds here and is the subject of the cross-class matrix.

The shape of the evidence travels. Peptides without a commercial sponsor accumulate mechanistic animal work and small human pharmacology studies. Peptides with one accumulate large randomised trials with clinical endpoints. The difference between those two literatures is not a difference in how promising the underlying biology is.

The community layer travels. Every compound here has a body of self-reported experience circulating alongside the published record, and its content is strikingly similar from class to class: injection-site reactions, fatigue in the first week, headache, a general sense of improvement. That similarity is itself a caution about how much of it is specific to any one molecule.

What does not travel is the biology. The receptor, the tissue, the direction of the effect and the strength of the evidence are compound-specific in every case. A generalisation about what a peptide does — as opposed to how long it lasts and what that permits — is almost always wrong, and this desk does not make one.